MetiMedi pharmaceuticals Co., LTD. – Trademark Portfolio
Entity Type: 03
MetiMedi pharmaceuticals Co., LTD. holds 4 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 2 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 3 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include METIMEDI and METI MEDI. The owner is based in Incheon.
Suite 908 IBS tower
263 Central-ro Yeonsu-gu
Incheon 22006 , KR
Showing of trademarks Trademarks
Trademark Classifications
MetiMedi pharmaceuticals Co., LTD.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does MetiMedi pharmaceuticals Co., LTD. have?
MetiMedi pharmaceuticals Co., LTD. has 4 U.S. trademarks filed with the USPTO. Of these, 3 registered, 1 abandoned.
What trademark classes does MetiMedi pharmaceuticals Co., LTD. file in?
MetiMedi pharmaceuticals Co., LTD. files trademarks across 3 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 5 (Pharmaceuticals), Class 1 (Chemicals). Class 42 covers scientific and technological services; industrial analysis and research services.
What are MetiMedi pharmaceuticals Co., LTD.'s most well-known trademarks?
MetiMedi pharmaceuticals Co., LTD.'s registered trademark portfolio includes well-known marks such as METIMEDI and METI MEDI. These are among 3 currently registered trademarks in the portfolio.
What is MetiMedi pharmaceuticals Co., LTD.'s trademark registration success rate?
MetiMedi pharmaceuticals Co., LTD. has a 75% trademark registration rate, with 3 out of 4 resolved applications resulting in successful registration. Currently, 0 applications are pending review.